Thrombolytic therapy with alteplase for ischaemic stroke

Drug and Therapeutics Bulletin

Volumn 47, Issue 2, 2009, Pages 14-18

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; DESMOTEPLASE; PLACEBO; STREPTOKINASE; UROKINASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COST OF ILLNESS; DISEASE SEVERITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DRUG SAFETY; FIBRINOLYTIC THERAPY; GLASGOW COMA SCALE; HUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PROGNOSIS; RANKIN SCALE; UNITED KINGDOM; AGED; BRAIN ISCHEMIA; ECONOMICS; EMERGENCY TREATMENT; LITERATURE; REVIEW; STROKE;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUG COSTS; EMERGENCY TREATMENT; FIBRINOLYTIC AGENTS; HUMANS; REVIEW LITERATURE AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 67650039772     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2009.01.0001     Document Type: Article

References (42)

1. DH/ Vascular Programme/ Stroke. A new ambition for stroke. A consultation on a national strategy. London: Department of Health, 2007.
2. National Institute for Health and Clinical Excellence, 2008. Stroke: diagnosis and initial management of acute stroke and transient ischaemic attack (TIA). NICE clinical guideline 68 [online]. Available: http://www.nice.org. uk/nicemedia/pdf/CG68NICEGuideline.pdf [Accessed 23 January2009].
3. Division of Health and Social Care Research, King's College London.Economic burden of stroke in England [online]. Available: http://www.nao.org.uk/system-pages/idoc.ashx?docid=11ed54b8-babf-4c0e-aefc- 2a09b55de4ae&version=-1 [Accessed 23 January 2009].
4. Hudson J et al. Joining forces to deliver improved stroke care. London: The National Audit Office 2007.
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
6. Poppe AY, Hill MD. Acute ischaemic stroke in patients aged 80 years and older. Drugs Aging 2008; 25: 95-103.
7. Warlow C et al. A practical approach to the management of stroke and transient ischaemic attack. Stroke: practical management Third Edition. Blackwell Publishing: Oxford, 2008.
8. Adams HP et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34: 1056-83.
9. Hacke W et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-29.
10. Albers GW et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283: 1145-50.
11. Wahlgren N et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-82.
12. Wardlaw JM et al. Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD000213. DOI: 10.1002/14651858. CD000213 [Date of most recent substantive amendment 14 March 2003].
13. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 56-61.
14. Jennett B, Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet 1975; 1: 480-4.
15. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol 2006; 5: 603-12.
16. Rajajee V et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology 2006; 67: 980-4.
17. Saver JL. Time is brain-quantified. Stroke 2006; 37: 263-6.
18. Nor AM et al. The Recognition of Stroke in the Emergency Room (ROSIER) scale: development and validation of a stroke recognition instrument. Lancet Neurol 2005; 4: 727-34.
19. Pettersen JA et al. Intra-arterial thrombolysis in acute ischemic stroke: a review of pharmacologic approaches. Expert Rev Cardiovasc Ther 2004; 2: 285-99.
20. Kendall J. Thrombolysis for acute ischaemic stroke: a new challenge for emergency medicine. Emerg Med J 2008; 25: 471-5.
21. US Food and Drug Administration Center for Drug Evaluation and Research, 1996. Alteplase. Summary basis of approval [online]. Available: http://www.fda.gov/CDER/biologics/sba/altegen0618965.pdf [Accessed 23 January 2009].
22. Ingall TJ et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004; 35: 2418-24.
23. Clark WM et al. The rt-PA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000; 31: 811-6.
24. Clark WM et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: A randomized controlled trial. JAMA 1999; 282: 2019-26.
25. Saver JL, Yafeh B. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials. Stroke 2007; 38: 414-6.
26. Kwiatkowski TG et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999; 340: 1781-7.
27. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-74.
28. Actilyse. Summary of product characteristics, EU. Boehringer Ingelheim Limited, April 2004.
29. National Institute for Health and Clinical Excellence, 2007. Alteplase for the treatment of acute ischaemic stroke. NICE technology appraisal guidance 122 [online]. Available: http://http://www.nice.org.uk/nicemedia/pdf/ TA122guidance.pdf guidance.pdf [Accessed 23 January 2009].
30. Scottish Medicines Consortium, 2004. Alteplase (Actilyse). No. 87/04 [online]. Available: http://www.scottishmedicines.org.uk/smc/files/ Alteplase.pdf [Accessed 23 January 2009].
31. The European Stroke Initiative Executive Committee, the EUSI Writing Committee. European Stroke Initiative recommendations for stroke management - update 2003. Cerebrovasc Dis 2003; 16: 311-37.
32. Adams HP et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke 2007; 38: 1655-711.
33. th edition). Chest 2008; 133: 630S-699S.
34. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172: 1307-12.
35. Royal College of Physicians of London 2008. National Sentinel Stroke Audit Phase 1 Organisational audit 2008. Report for England, Wales and Northern Ireland [online]. Available: http://www.rcplondon.ac.uk/Clinical-Standards/ ceeu/Current-work/Documents/Public%organisation%20report2008.pdf [Accessed 23 January 2009].
36. Davis SM et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7: 299-309.
37. The National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 2005; 46: 243-52.
38. Sandercock P et al. The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials 2008; 9: 37 doi: 10.1186/1745-6215-9-37.
39. Adams H et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update. A scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005; 36: 916-23.
40. Wahlgren N et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-9.
41. Baumann CR et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 2006; 37: 1332-3.
42. De Keyser J et al. Intravenous alteplase for stroke. Beyond the guidelines and in particular clinical situations. Stroke 2007; 38: 2612-8.